Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04183166 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

A Phase 1 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Transgene.

Active
Registry status
Phase 1
Development phase
80
Enrollment target
14
Study locations

NCT04183166: Active Phase 1 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Transgene.

NCT04183166 is a Phase 1 study of Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by Transgene. The registered enrollment target is 80 participants, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (52% lower). The trial reports 14 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04183166, a Phase 1 study of Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by Transgene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
14
Study locations

Study Summary

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Primary Outcome

Incidence of Adverse Event reported per CTCAE v5.

Interventions

  • DRUG TG4050

Study Locations (14)

Other

  • Hôpital Saint André - CHU de Bordeaux - Bordeaux
  • Hôpital de la Timone - Marseille
  • Institut Curie - Paris
  • IUCT Toulouse - Toulouse
  • Institut Gustave Roussy - Villejuif
  • Hospital Universitari Vall d Hebrón - Barcelona
  • Institut Català d Oncologia - Hospital Duran i Reynals - Barcelona
  • Hospital Clínico San Carlos - Madrid
  • Hospital Universitario La Paz - Madrid
  • Hospital Regional Universitario de Málaga - Hospital Civil - Málaga
  • Complejo Hospitalario Universitario de Santiago - Santiago de Compostela
  • NHS Clatterbridge Cancer Center - Liverpool
  • Aintree University Hospital NHS Fondation Trust - Liverpool

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2019-12-12
Est. Completion 2031-12-30
Phase Phase 1
Transgene

7 total trials

What the registry record for NCT04183166 still lists

NCT04183166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (52% lower).

The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which TG4050 is the first listed.

NCT04183166 lists 14 locations in 2 states (Other, Florida).

Frequently Asked Questions

What is clinical trial NCT04183166 about?

NCT04183166 is a clinical study titled "A Clinical Trial Evaluating TG4050 in Head and Neck Cancer". This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

What is the current status of trial NCT04183166?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2019-12-12. Estimated completion is 2031-12-30.

What conditions does trial NCT04183166 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT04183166?

The interventions under investigation include: TG4050 (DRUG).

Who is sponsoring clinical trial NCT04183166?

This trial is sponsored by Transgene, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04183166 being conducted?

This trial has 14 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04183166's enrollment target sits among peer trials

80 17th of 37 higher than 21 of 37 other Squamous Cell Carcinoma of Head and Neck trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04183166, the US trial registry maintained by the National Library of Medicine. NCT04183166 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.